Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.56 |
| ▸ | S100A10 | P60903 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | FPR1 | P21462 | 3/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303883 | 0.92 | KDM4E (0.64) | KDM4ECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL4293908 | 0.92 | RXFP1 (0.62) | KDM4ECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL4295255 | 0.91 | KDM4E (0.76) | KDM4ECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL4297972 | 0.91 | MEN1 (0.77) | KDM4ECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL4295941 | 0.89 | KDM4E (0.58) | KDM4ECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL4291591 | 0.86 | KDM4E (0.55) | KDM4ECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL4295483 | 0.86 | KDM4E (0.60) | KDM4ECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL4295338 | 0.86 | KDM4E (0.68) | KDM4ECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL4295951 | 0.85 | KDM4E (0.53) | KDM4ECYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL4299743 | 0.84 | ANXA2 (0.58) | KDM4ECYP3A4CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | claimed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | claimed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | KDM4E 2532/4885CYP3A4 1738/4885CYP2C9 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.